Systems Biology Opens the Blackest Boxes
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
FDA: Too Restrictive?
In a debate held on May 8, 2013, major thinkers argued over whether or not the FDA is failing its mandate of protecting the public health, as its approval processes can slow the process of bringing new treatments to market. The debate featured a poll asking participants if they agree with the statement “The FDA’s caution is hazardous to our health.” The results: before the debate, 24% were in favor of that statement, 32% were against it, and 44% were undecided; after the debate, 53% were in favor, 38% were against it, and 9% were undecided. Now, we’re asking GEN readers a similar question.